ABSTRACT
Background In Duchenne muscular dystrophy (DMD), fibrosis is linked to connective tissue growth factor (CTGF) overexpression. Pamrevlumab, a fully human monoclonal antibody, inhibits CTGF activity and showed promise as a DMD treatment in a phase 2 trial.
Objective LELANTOS-1 (NCT04371666) was a global phase 3 study of the safety and efficacy of pamrevlumab for non-ambulatory males ≥12 years old with DMD.
Methods Patients were randomized 1:1 to pamrevlumab 35 mg/kg every 2 weeks for 52 weeks or placebo. All received a stable corticosteroid regimen (deflazacort or prednisone/prednisolone). Primary endpoint was total Performance of Upper Limb (PUL) v2.0 score change from baseline to Week 52 in the modified intent-to-treat (mITT) set (baseline PUL score ≥2). Treatment-emergent adverse events (TEAEs) were noted. Patients who completed the main study period were eligible to enroll in the open-label extension (OLE).
Results Ninety-eight patients (mean [SD] age, 15.5 [2.57] years) enrolled; 48 received pamrevlumab and 49 received placebo. Between-group baseline characteristics were similar. In the mITT set (mean [SD] age, 15.5 [2.64] years; pamrevlumab, n=41; placebo, n=42), the total PUL v2.0 score change was not significantly different (p=0.8802). The pamrevlumab group had more grip strength deterioration than placebo in dominant (p=0.0161) and nondominant hands (p=0.0052). Most patients (pamrevlumab, n=45/48 [93.8%]; placebo, n=48/49 [98.0%]) experienced TEAEs (most mild/moderate). One death occurred in the pamrevlumab group (unrelated to study drug). The OLE mITT set included 72 patients. OLE efficacy and safety were consistent with the main study period. No deaths occurred during the OLE.
Conclusions Pamrevlumab failed to meet the primary endpoint. Its future as a DMD treatment is uncertain.
Trial Registration ClinicalTrials.gov Identifier: NCT04371666
Competing Interest Statement
AMC has received grants and reports serving on a advisory board for Edgewise Therapeutics and Sarepta. BLW, YP, SW, and XC report nothing to disclose. HCP served as a principal investigator for Applied Therapeutics, Avidity, Biogen, Biohaven, Dyne, Edgewise, Italfarmaco, NMD Pharma, NS Pharma, PepGen, Sarepta, Stealth, Takeda, Ultragenyx, and Zynerba. She also serves on the advisory board for Tyra and an advisory committee for the FDA. EM has received honoraria for scientific advisory boards and educational speaker fees from Biogen, Novartis, F. Hoffmann-La Roche, Sarepta Therapeutics, Santhera, PTC Therapeutics, Pfizer, Scholar Rock, and Cytokinetics, and has received research support grants from Biogen. CT received grants for serving as a site investigator for this study and for clinical trials and studies sponsored by Novartis, BioHaven, Capricor, Catabasis, MDA, PTC Therapeutics, and Sarepta, and received personal fees for serving as a member of advisory boards for Pfizer, Catalyst, ITF, and Sarepta, and grants for serving as co-PI for the National Institutes of Health-sponsored TSC-STEPS study. SDL has served as a PI for FibroGen and Genethon, on an advisory board for Solid, and as a consultant for Effik/Italfarmaco Group. SFN reports study fees paid to UCLA by FibroGen for this clinical trial. SCP hasreceived support from FibroGen for this clinical trial; support from Wave, Dyne, Argenx, and Jannsen for clinical trials; personal fees for scientific boards from Wave, Esperare, and Argenx; and grants from Fondazione ricerca regione lombardia for a clinical trial, and Telethon Italy for a natural history study. OVG was an employee of FibroGen at the time of the study, with restricted stock grants. EC is an employee of FibroGen and owns stock options. JFB received personal fees from AveXis/Novartis, Biogen, Dyne, Edgewise, FibroGen, Genentech, Momenta/Janssen, NS Pharma, Pfizer, PTC Therapeutics, Sarepta, Scholar Rock, Takeda, and WaVe. He has received grants from Alexion, Astellas, AveXis/Novartis, Biogen, Biohaven, Catabasis, CSL Behring, Cytokinetics, Dyne, Fibrogen, Genentech, ML Bio, Pfizer, PTC Therapeutics, Sarepta, and Scholar Rock.
Clinical Trial
NCT04371666
Funding Statement
Funding for this study was provided by FibroGen, Inc. (San Francisco, CA, USA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice (GCP), the International Council for Harmonisation E6 Guidance for GCP, and any other applicable local health and regulatory requirements. The study was approved by the respective institutional review boards at each participating study site, and written informed consent was obtained from each patient or their legal guardian. See Table S1 in supplement for full details.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos